专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5602140A Purine derivatives and suppressants for inflammatory diseases 失效
标题翻译：嘌呤衍生物和抑制剂用于炎性疾病
公开(公告)号：US5602140A
公开(公告)日：1997-02-11
申请号：US410838
申请日：1995-03-27
申请人： Yoshiaki Isobe , Nobuyoshi Chiba , Yuso Goto , Hideharu Sato
发明人： Yoshiaki Isobe , Nobuyoshi Chiba , Yuso Goto , Hideharu Sato
IPC分类号： C07D233/90 , C07D473/30 , A61K31/52
CPC分类号： C07D473/30
摘要： Purine derivatives shown by general formula [I] or pharmacologically acceptable salts thereof. Suppressants for inflammatory diseases containing an effective ingredient of said purine derivative. ##STR1## (wherein, R represents one group selected from the groups composed of H atom, a straight chain alkyl group having 1-10 carbon atoms, a branched chain alkyl group having 3-10 carbon atoms, an alkyl group having 1-10 carbon atoms substituted with one carboxyl group, 4-carboxybenzyl group and phenethyl group).Above mentioned purine derivatives prevent the tissue damages due to mediators such as active oxygen and TXA.sub.2 in the initial stage of inflammation, and prevent the subsequent aggravation of inflammatory responses due to the adhesion of activated leukocytes to the cells in the lesion, and exhibit efficacy as anti-inflammatory drugs in all stages of inflammatory diseases caused by leukocytes.
摘要翻译：由通式[I]表示的嘌呤衍生物或其药理学上可接受的盐。含有所述嘌呤衍生物的有效成分的炎性疾病抑制剂。（I）（I）（其中，R表示选自由H原子，具有1-10个碳原子的直链烷基，具有3-10个碳原子的支链烷基组成的基团中的一个基团， 1-10个碳原子被一个羧基取代，4-羧基苄基和苯乙基）。上述嘌呤衍生物可防止炎症初期由于诸如活性氧和TXA2等介质而导致的组织损伤，并且防止由于活化的白细胞粘附于病变中的细胞而导致的炎性反应的随后恶化，抗炎药物在白细胞引起的炎症性疾病的各个阶段。

2. 发明授权

US5661153A 1-arylpyrimidine derivatives and pharmaceutical use thereof 失效
标题翻译： 1-芳基嘧啶衍生物及其药物用途
公开(公告)号：US5661153A
公开(公告)日：1997-08-26
申请号：US463277
申请日：1995-06-05
申请人： Yoshiaki Isobe , Toshimasa Katagiri , Junko Umezawa , Yuso Goto , Masashi Sasaki , Nobuo Watanabe , Hideharu Sato , Fumihiro Obara
发明人： Yoshiaki Isobe , Toshimasa Katagiri , Junko Umezawa , Yuso Goto , Masashi Sasaki , Nobuo Watanabe , Hideharu Sato , Fumihiro Obara
IPC分类号： C07D239/54 , C07D239/545 , C07D473/04 , C07D473/06 , A61K31/52
CPC分类号： C07D239/545 , C07D473/04 , C07D473/06
摘要： The present invention relates to 1-arylpyrimidine derivatives represented by general formula (I): ##STR1## wherein R.sub.1 is H, alkyl or aralkyl;Ar is 1-naphthyl, or a substituted or unsubstituted phenyl group;R.sub.4 is a substituted phenyl, a substituted styryl, 1-methylcyclohexyl, 4-methylcyclohexyl, 4-oxo-4H-pyran-2-yl or 2-oxo-2H-pyran-5-yl group;R.sub.5 and R.sub.6 are each independently H or alkyl;R.sub.3 is H, and R.sub.7 and R.sub.8 are combined together to be oxo, or else R.sub.3 and R.sub.7 are combined together to be another direct bond, and R.sub.5 and R.sub.8 are combined together to be a direct bond,or pharmaceutically acceptable salts thereof; and methods for treating allergic diseases with such compounds.
摘要翻译：本发明涉及由通式（I）表示的1-芳基嘧啶衍生物：Ar是1-萘基或取代或未取代的苯基; R4是取代的苯基，取代的苯乙烯基，1-甲基环己基，4-甲基环己基，4-氧代-4H-吡喃-2-基或2-氧代-2H-吡喃-5-基; R5和R6各自独立地为H或烷基; R3为H，R7和R8组合在一起为氧代，或者R3和R7组合在一起成为另一个直接键，R5和R8组合在一起成为直接键，或其药学上可接受的盐; 以及用这些化合物治疗过敏性疾病的方法。

3. 发明授权

US5877318A Hydroquinone derivative and pharmaceutical use thereof 失效
标题翻译：对苯二酚衍生物及其药物用途
公开(公告)号：US5877318A
公开(公告)日：1999-03-02
申请号：US113826
申请日：1998-07-10
申请人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
发明人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
IPC分类号： C07D239/54 , C07D239/545 , C07D405/12
CPC分类号： C07D239/545 , C07D405/12
摘要： Disclosed is a hydroquinone derivative or a pharmaceutically acceptable salt thereof, the hydroquinone derivative being represented by formula (I): ##STR1## wherein R.sup.1 is a phenyl group which is unsubstituted or substituted with a substituent or substituents each independently selected from the group consisting of a halogen atom, a C1-4 alkyl group and a C1-4 alkoxy group;R.sup.2 is a hydrogen atom or a C1-4 alkyl group;each of R.sup.3 and R.sup.4 is independently a hydrogen atom or a C1-4 alkyl group;R.sup.5 is a hydrogen atom or a C1-4 alkyl group;each of R.sup.6, R.sup.7 and R.sup.8 is independently a hydrogen atom or a C1-4 alkyl group;P is a hydroxyl group;Q is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group;P may form together with Q an ether bond;R is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group, provided that when one of said Q and said R is an oxo group, the other is also an oxo group;X is a single bond, an --NR.sup.10 -- group or a --CH.sub.2 --NR.sup.10 -- group in which R.sup.10 is a hydrogen atom or a C1-4 alkyl group;Y is a methylene group or a carbonyl group; anddotted bonds in a six membered ring represent that said six membered ring has the maximum number of double bonds.
摘要翻译：公开了氢醌衍生物或其药学上可接受的盐，氢醌衍生物由式（I）表示：未取代或被各自独立地选自卤素原子，C 1-4烷基的取代基或取代基取代和C 1-4烷氧基; R2是氢原子或C1-4烷基; R 3和R 4各自独立地为氢原子或C 1-4烷基; R5是氢原子或C1-4烷基; R6，R7和R8各自独立地为氢原子或C1-4烷基; P是羟基; Q是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基; P可与Q形成醚键; R是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基，条件是当所述Q和所述R中的一个是氧代基时，另一个也是氧代基; X是单键，-NR 10 - 基或-CH 2 -NR 10 - 基，其中R 10是氢原子或C 1-4烷基; Y是亚甲基或羰基; 六元环中的点状键表示所述六元环具有最大数量的双键。

4. 发明授权

US5821247A Hydroquinone derivative and pharmaceutical use thereof 失效
标题翻译：对苯二酚衍生物及其药物用途
公开(公告)号：US5821247A
公开(公告)日：1998-10-13
申请号：US933208
申请日：1997-09-16
申请人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
发明人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
IPC分类号： C07D239/54 , C07D239/545 , C07D405/12 , A61K31/51
CPC分类号： C07D239/545 , C07D405/12
摘要： Disclosed is a hydroquinone derivative or a pharmaceutically acceptable salt thereof, the hydroquinone derivative being represented by formula (I): ##STR1## wherein R.sup.1 is a phenyl group which is unsubstituted or substituted with a substituent or substituents each independently selected from the group consisting of a halogen atom, a C1-4 alkyl group and a C1-4 alkoxy group; R.sup.2 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.3 and R.sup.4 is independently a hydrogen atom or a C1-4 alkyl group; R.sup.5 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.6, R.sup.7 and R.sup.8 is independently a hydrogen atom or a C1-4 alkyl group; P is a hydroxyl group; Q is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group; P may form together with Q an ether bond; R is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group, provided that when one of said Q and said R is an oxo group, the other is also an oxo group; X is a single bond, an --NR.sup.10 --group or a --CH.sub.2 --NR.sup.10 --group in which R.sup.10 is a hydrogen atom or a C1-4 alkyl group; Y is a methylene group or a carbonyl group; and dotted bonds in a six membered ring represent that said six membered ring has the maximum number of double bonds.
摘要翻译：公开了氢醌衍生物或其药学上可接受的盐，所述对苯二酚衍生物由式（I）表示：未取代的或被各自独立地选自卤素原子，C 1-4烷基的取代基或取代基取代和C 1-4烷氧基; R2是氢原子或C1-4烷基; R 3和R 4各自独立地为氢原子或C 1-4烷基; R5是氢原子或C1-4烷基; R6，R7和R8各自独立地为氢原子或C1-4烷基; P是羟基; Q是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基; P可与Q形成醚键; R是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基，条件是当所述Q和所述R中的一个是氧代基时，另一个也是氧代基; X是单键，-NR 10 - 基或-CH 2 -NR 10 - 基，其中R 10是氢原子或C 1-4烷基; Y是亚甲基或羰基; 六元环中的点状键表示所述六元环具有最大数量的双键。

5. 发明授权

US5849779A Pyrazole derivatives and their pharmaceutical use 失效
标题翻译：吡唑衍生物及其药物用途
公开(公告)号：US5849779A
公开(公告)日：1998-12-15
申请号：US864076
申请日：1997-05-28
申请人： Kohsaku Hirota , Hironao Sajiki , Yoshiaki Isobe , Yoichi Ohba , Hiroyuki Morita , Haruo Takaku , Nobuyoshi Chiba
发明人： Kohsaku Hirota , Hironao Sajiki , Yoshiaki Isobe , Yoichi Ohba , Hiroyuki Morita , Haruo Takaku , Nobuyoshi Chiba
IPC分类号： A61K31/415 , C07D231/40 , C07D231/04
CPC分类号： C07D231/40 , A61K31/415
摘要： The present invention relates to a pyrazole derivative represented by formula (I) or (II) ##STR1## wherein R.sup.1 is hydrogen C2-C6 alkyl benzyl or phenyl; each of R.sup.2 and R.sup.3 is hydrogen, C1-C6 alkyl or benzyl; each of R.sup.4 and R.sup.5 is hydrogen, C1-C6 alkyl, C3-C6 alkenyl, C3-C8 cycloalkyl, benzyl or phenyl; X is oxygen or sulfur; R.sup.5 is hydrogen, C2-C6 alkyl, C3-C6 alkenyl, C3-C8 cycloalkyl or benzyl when R.sup.1 is benzyl, R.sup.2 is ethyl, R.sup.3 is hydrogen, and R.sup.4 is hydrogen, and its pharmaceutical use.
摘要翻译：本发明涉及由式（I）或（II）表示的吡唑衍生物，苄基或苯基; R2和R3各自为氢，C1-C6烷基或苄基; R 4和R 5各自为氢，C 1 -C 6烷基，C 3 -C 6烯基，C 3 -C 8环烷基，苄基或苯基; X是氧或硫; 当R1是苄基，R2是乙基，R3是氢，R4是氢时，R5是氢，C2-C6烷基，C3-C6烯基，C3-C8环烷基或苄基，以及其药物用途。

6. 发明授权

US06028076A Purine derivative 失效
标题翻译：嘌呤衍生物
公开(公告)号：US06028076A
公开(公告)日：2000-02-22
申请号：US29076
申请日：1998-03-03
申请人： Kohsaku Hirota , Yoshiaki Isobe , Nobuyoshi Chiba , Harumi Satoh , Haruo Takaku , Hiroyuki Matsui , Haruhisa Ogita
发明人： Kohsaku Hirota , Yoshiaki Isobe , Nobuyoshi Chiba , Harumi Satoh , Haruo Takaku , Hiroyuki Matsui , Haruhisa Ogita
IPC分类号： C07D473/00 , C07D473/30 , C07D473/34 , A61K31/52 , C07D473/38
CPC分类号： C07D473/00 , C07D473/30 , C07D473/34
摘要： This invention relates to novel purine derivatives of formula (I): ##STR1## where R.sup.2 and R.sup.9 are hydrocarbon groups, R.sup.6 is an amino group and R.sup.8 is a hydroxyl, or acyloxy group. These purine derivatives are effective at promoting secretion of interferon in patients, and can be used to treat diseases against which interferon is effective.
摘要翻译： PCT No.PCT / JP97 / 02310 Sec。 371日期1998年3月3日 102（e）1998年3月3日PCT PCT 1997年7月3日PCT公布。出版物WO98 / 01448 日本1998年1月15日本发明涉及式（I）的新型嘌呤衍生物：其中R2和R9为烃基，R6为氨基，R8为羟基或酰氧基。这些嘌呤衍生物有效促进患者的干扰素分泌，并可用于治疗干扰素有效的疾病。

7. 发明授权

US08476288B2 Salts 756 有权
标题翻译：盐756
公开(公告)号：US08476288B2
公开(公告)日：2013-07-02
申请号：US12784226
申请日：2010-05-20
申请人： Nicholas James Bennett , Thomas McInally , Austen Pimm , Yoshiaki Isobe
发明人： Nicholas James Bennett , Thomas McInally , Austen Pimm , Yoshiaki Isobe
IPC分类号： A61K31/505 , C07D239/48
CPC分类号： C07D239/49 , C07D275/06
摘要： The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.
摘要翻译：本发明提供2-（4 - （（2-氨基-4-甲基-6-（戊基氨基）嘧啶-5-基）甲基）苯基）乙酸4-（二甲基氨基）丁酯的盐，含有它们的药物组合物及其用途在治疗。

8. 发明申请

US20100099870A1 NOVEL ADENINE COMPOUND 失效
标题翻译：新颖的化合物
公开(公告)号：US20100099870A1
公开(公告)日：2010-04-22
申请号：US12531867
申请日：2008-03-19
申请人： Yoshiaki Isobe , Tomoaki Nakamura
发明人： Yoshiaki Isobe , Tomoaki Nakamura
IPC分类号： C07D473/18
CPC分类号： C07D473/18 , C07D473/00
摘要： A novel adenine compound represented by the formula (1): [wherein R1 is substituted or unsubstituted alkyl, etc., X is oxygen, etc., A1 is 4- to 8-membered substituted or unsubstituted saturated nitrogen-containing heterocycle containing 1 to 2 hetero atom(s) selected from 1 to 2 nitrogen(s), 0 to 1 oxygen and 0 to 1 sulfur, etc., A2 is substituted or unsubstituted 6- to 10-membered aryl, etc., L1 and L2 are independently a straight chain or branched chain alkylene, etc.], or a pharmaceutically acceptable salt thereof, which is useful as a medicament.
摘要翻译：由式（1）表示的新型腺嘌呤化合物：其中，R 1为取代或未取代的烷基等，X为氧等，A 1为4〜8元的取代或未取代的饱和含氮杂环， 2个选自1至2个氮，0至1个氧和0至1个硫等的杂原子，A2为取代或未取代的6-至10-元芳基等，L1和L2独立地为直链或支链亚烷基等]或其药学上可接受的盐，其可用作药物。

9. 发明申请

US20100011423A1 User identification system and a method thereof 有权
标题翻译：用户识别系统及其方法
公开(公告)号：US20100011423A1
公开(公告)日：2010-01-14
申请号：US12379639
申请日：2009-02-26
申请人： Yoshiaki Isobe , Takao Murakami , Kenta Takahashi
发明人： Yoshiaki Isobe , Takao Murakami , Kenta Takahashi
IPC分类号： H04L9/32 , G06F21/00
CPC分类号： G06F21/32 , G06F21/31 , G07C9/00158
摘要： A service providing system using the biometrics identification without inputting the user ID poses the problem that the consideration of a service is erroneously claimed to the registered user not using the service due to the erroneous identification. According to this invention, the threshold of the value of the degree of similarity for user identification is set strictly for each registered biometrics information of the user in accordance with the declaration of the loss caused by the erroneous identification.
摘要翻译：在不输入用户ID的情况下使用生物特征识别的服务提供系统造成了由于错误识别而使服务错误地要求给注册用户不使用服务的问题。根据本发明，根据由错误识别引起的损失的声明，对用户的每个登记生物特征信息严格地设定用户识别度的相似度值的阈值。

10. 发明申请

US20090307764A1 Biometric Authenticaton System and Method with Vulnerability Verification 失效
标题翻译：生物特征识别系统和脆弱性验证方法
公开(公告)号：US20090307764A1
公开(公告)日：2009-12-10
申请号：US12293470
申请日：2007-03-23
申请人： Yoshiaki Isobe , Masahiro Mimura
发明人： Yoshiaki Isobe , Masahiro Mimura
IPC分类号： H04L9/32 , G06F21/20
CPC分类号： G06F21/32 , G06F21/51 , G06F21/577 , G06F2221/2101 , H04L9/3231
摘要： A biometric authentication device has a threat of an attack of pretending to be someone else by such as forgery. The present invention supports a service provider to appropriately decide the level of such threat.A vulnerability verification server 150 is provided in the system, and the vulnerability of each biometric product is centrally managed. A service provider 130 sends the information that specifies the device in which a client terminal 110 executes the biometric authentication to the vulnerability verification server 150, and receives the vulnerability information. The service provider 130 decides whether the service can be provided or not to the client terminal 110 using the vulnerability information that was received.
摘要翻译：生物识别认证设备有伪装的假冒伪装的威胁。本发明支持服务提供商适当地确定这种威胁的程度。系统中提供了一个漏洞验证服务器150，并且集中管理每个生物特征产品的漏洞。服务提供者130将指定客户终端110的设备的信息发送到漏洞验证服务器150，并接收该漏洞信息。服务提供者130使用接收到的漏洞信息来判定是否可以向客户终端110提供服务。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式